EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Late Onset Thrombotic Microangiopathy in Kidney Transplants; Poor Outcome Despite Eculizumab Treatment

Emily K Glover, Emma K Montgomery, Edwin K S Wong, Sally Johnson, Michal Malina, Kevin J Marchbank, David Kavanagh, Neil S Sheerin

Transplant International · 2025

DOI: 10.3389/ti.2025.15404 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant International, 2025. Verfasst von Emily K Glover und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Kidney Transplantation, Thrombotic Microangiopathies, Kidney Failure, Chronic. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Northern Counties Kidney Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atypical hemolytic uremic syndrome (aHUS) is a rare cause of end stage kidney disease (ESKD) associated with a high rate of recurrence in kidney transplants causing a post-transplant thrombotic microangiopathy (TMA). Prophylactic eculizumab can prevent disease recurrence in select patients. Treating at the time of post-transplant TMA occurrence is the only option if the diagnosis of aHUS is not established pre-transplant. We report our experience of using eculizumab at the point of post-transplant TMA in those with a diagnosis or suspicion of aHUS. We conducted a case note review of 26 patients treated with eculizumab for post-transplant TMA. Screening for complement pathway defects included testing for variants in genes of the complement pathway and anti-factor H autoantibodies. 34.6% of recipients had an identified complement pathway defect. Median time to presentation with post-transplant TMA was 8.4 months. Death-censored graft survival 12 months after starting eculizumab was 68% for the cohort and was worse in those presenting >12 months post-transplant where this figure was 42.9%. The outcome is poor despite eculizumab treatment for those presenting >12 months after transplantation with TMA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedKidney TransplantationThrombotic MicroangiopathiesKidney Failure, ChronicHumansFemaleMaleMiddle AgedAdultAtypical Hemolytic Uremic SyndromeTreatment OutcomeGraft SurvivalRetrospective StudiesAgedComplement Inactivating AgentsYoung Adult

Stichwörter der Autor:innen

aHUSeculizumabkidneyrare diseaserecurrencethrombotic microangiopathytransplantation

Substanzen

eculizumabAntibodies, Monoclonal, HumanizedComplement Inactivating Agents

Autor:innen und Institutionen

  • National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.
  • Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Great North Children's Hospital, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.

Förderung

  • Wellcome Trust
  • Northern Counties Kidney Research Fund

Zitieren

APA

Glover, E. K., Montgomery, E. K., Wong, E. K. S., Johnson, S., Malina, M., Marchbank, K. J., Kavanagh, D., & Sheerin, N. S. (2025). Late Onset Thrombotic Microangiopathy in Kidney Transplants; Poor Outcome Despite Eculizumab Treatment. Transplant International. https://doi.org/10.3389/ti.2025.15404

Vancouver

Glover EK, Montgomery EK, Wong EKS, Johnson S, Malina M, Marchbank KJ, et al. Late Onset Thrombotic Microangiopathy in Kidney Transplants; Poor Outcome Despite Eculizumab Treatment. Transplant International. 2025. doi:10.3389/ti.2025.15404

BibTeX
@article{Glover2025,
  author = {Glover, Emily K and Montgomery, Emma K and Wong, Edwin K S and Johnson, Sally and Malina, Michal and Marchbank, Kevin J and Kavanagh, David and Sheerin, Neil S},
  title = {Late Onset Thrombotic Microangiopathy in Kidney Transplants; Poor Outcome Despite Eculizumab Treatment},
  journal = {Transplant International},
  year = {2025},
  doi = {10.3389/ti.2025.15404}
}
Kostenlos starten →